Navigation Links
New Study Shows Many U.S. Contact Lens Wearers Do Not Comply With Recommended Replacement Schedules
Date:6/4/2009

were worn on a daily wear basis for 12.8 +/- 3.2 hours per day, 6.2 +/- 1.5 days a week. The distribution of lens types was 16 percent daily disposable, 45 percent two-week replacement silicone hydrogel and 39 percent one-month replacement silicone hydrogel. Eye care practitioners were asked to provide lens information and their recommendation for replacement schedules after the surveys had been completed and sealed in envelopes. All responses were anonymous.

About Centre for Contact Lens Research
Established in 1988 at the University of Waterloo's School of Optometry, the Centre for Contact Lens Research is a globally recognized organization that performs clinical research investigating the ocular response to contact lenses and other forms of vision correction. Working in partnership with industry affiliates and collaborating with both local and international researchers, the organization’s clinical trials focus on conventional and silicone hydrogel materials, rigid gas permeable lenses, lens care products, orthokeratology, and the ocular effects of refractive surgery.

About CIBA VISION
With a shared passion for healthy vision and better life, CIBA VISION is a global leader in the research, development and manufacturing of contact lenses and lens care products. CIBA VISION is dedicated to improving the quality of patients’ lives around the world through innovative vision care solutions and strong partnerships with eye care professionals. With worldwide headquarters in Atlanta, CIBA VISION products are available in more than 70 countries around the world. For more information, visit the CIBA VISION web site at www.cibavision.com.

Media Contact
Brandi Robinson
Vice President, North America Communications
678.415.3482

Katie Hogan
MS&L
404.870.6846

###

Read the full story at <
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...tes Department of Agriculture (USDA) has awarded a... University of Minnesota to complete sequencing th...lopavo. The funding will be used by the Turkey Gen...equencing using next-generation sequencing platfor...es and functions in the final genome sequence by u...
(Date:11/23/2009)...-FirstCall/--AnnTaylorStoresCorp.announcedtodaytha...lThanksandGivingcampaign,aholidayfundraisingandawa...ThisyearmarksthethirdyearthatAnnTaylor,throughitsA...nthecampaignwhereweofferourshoppersanopportunityto...ppingthisholidayseason.ClientswhoshopatAnnTaylor,L...
(Date:11/23/2009)...ire/--Thanksgivingweekendmarksthe36thannualStateFa...icrepresentsthesportsmanshipandprideoftwoschoolsbu...hoseinattendance. ,, ForthecrewofthenewU.S.Coas...mebeforetheyworktotestandlaunchabrandnewshiptoprot...ttyOfficerClaudeBovellandtherestofthecrewwillbegin...
(Date:11/23/2009)...ally modified to produce bacterial proteins that a...have been planted on more than 200 million hectare...ed after the bacterium Bacillus thuringiensis , c...allowing farmers to save money and lessen environm...However, since insects can evolve resistance to to...
(Date:11/23/2009)...ger to get sick, study finds , , MONDAY,...t a genetic variation appears to play a major role...tients. , In fact, those with the variation a... of complications of the disease. , "We,re ho...at make a person more or less susceptible to HIV, ...
Breaking Medicine News(10 mins):Health News:Turkey Genome Sequencing Consortium awarded $0.9 million from USDA 2Health News:Ann Taylor Stores Corp. Returns To St. Jude Children's Research Hospital's Thanks and Giving Campaign(R) For The Third Year 2Health News:Nothing Is Like Being There 2Health News:Insect resistance to Bt crops can be predicted, monitored and managed 2Health News:Genetic Variant Slows AIDS Progression 2
... Leading Researchers to Discuss, State of Breast ... Cures, BOSTON, April 9 The Massachusetts Affili...posium April 10 at Harvard Medical,School, featuri...d the need for more funding to ensure that critica...
...s becoming popular, survey finds , , WEDNE...ondents to a new survey acknowledges using so-call... heart medications -- to stimulate their focus, co...ut has emerged in recent years as a campus "study ...
...Care and Frida,Kahlo Store are proud to announce t...8 for the benefit of The Leukemia & Lymphoma Socie...sance, located at 2131 Hylan,Boulevard, Staten Isl... problems., The event will consist of a dinner-co...
...ia,Academy of Family Physicians Foundation (PAFP/F...amily medicine student scholarship programs., "Th...dle the continuing,demand for primary care," said ...we have to make sure they get every,opportunity to...
...n the United,States has doubled in the last 30 yea...tom lines, according to a new report from The Conf... fit the definition of "obese.",Obese employees co...yers Should Know about,Obesity, The Conference Boa...
...ingerprint associated with normal embryonic stem c...tion of cancer stem cells. The research, published...m Cell, demonstrates that embryonic stem cells and...nificant clinical implications for cancer therapeu...
Other Medicine News:Health News:Massachusetts Affiliate of Susan G. Komen for the Cure to Spotlight Gaps in Breast Cancer Research 2Health News:Unlikely Drugs Emerge as 'Cognition Enhancers' 2Health News:PAFP Golf Tournament to Benefit Student Programs 2Health News:Obesity Costs U.S. Companies as Much as $45 Billion a Year, The Conference Board Reports 2Health News:Obesity Costs U.S. Companies as Much as $45 Billion a Year, The Conference Board Reports 3Health News:Module map links embryonic stem cells and cancer stem cells 2
(Date:11/23/2009)...,Texas,Nov.23/PRNewswire-FirstCall/-- LexiconPharm...top-linedatafromitsPhase2clinicalstudywith LX1031 ...me(IBS)willbepresentedatGASTRO2009inLondonthisweek...ementinIBSsymptoms,willbepresentedbyDr. PhilipM.Br...ment,onNovember25,2009at2:30pmlocaltimeatthesessio...
(Date:11/23/2009)...xas,Nov.23/PRNewswire-FirstCall/--WoundManagementT...owingproviderofspecialtymedicalproducts,announcedt...dacomprehensivemanagementbusinessupdatetoillustrat...Q32009salesincreased33.5%to$102,926vs.Q32008saleso...reasedto$3,327,892vs.Q32008shareholderequityof$(32...
(Date:11/23/2009)...CISCO,Calif.,Nov.23/PRNewswire-FirstCall/--Anesiva...andDr.DavidC.U,PrichardhaveagreedtojointheAnesivab...gerbetweenAnesivaandArcionTherapeutics.Completiono...keplaceatthepreviouslyannouncedAnesiva2009AnnualMe...a.m.PSTat400OysterPoint,Suite107A,SouthSanFrancisc...
Breaking Medicine Technology:Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 2Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 1FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 2FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 3FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 4FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 5FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 6For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 1For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 2For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 3NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 1NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 2NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 3NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 4NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 5NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 6NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 7NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 8
...an Biosciences,Incorporated (Nasdaq: KOSN ) today...tanespimycin, the company,s lead Hsp90 inhibitor, ...(R) in patients with HER2-positive,metastatic brea...can,Society of Clinical Oncology (ASCO), being hel...une 3, 2008., Abstract 1027, titled, "Phase 2 tri...
... Review Data Tuesday, May 13 at 1:00 p.m. EDT ...A, Spain and MENLO PARK, Calif., May 13 /PRNewswir... announced positive six-month follow-up,data from ...safety and,efficacy of the Custom NX(R) drug eluti...s with coronary artery disease., The CUSTOM III c...
Other Medicine Technology:Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 2Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 3XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 2XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 3XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 4
...6 mm tip is angled 90 degrees with 1 mm flattened ...ure extension tube (0.03 inch ID x 8 inch long), f...r dissecting pre-retinal and other vitreo-retinal ..., angled tip of 30 gauge cannula facilitates place...
Vitreoretinal Micro Cannula
Moist Air Humidifying Chambers
Eye Garter Shield Cover - white
Medicine Products: